Ribociclib-induced acute kidney injury in patients with advanced-stage breast cancer: A case series and literature review

Introduction: The phase-3 MONALEESA-2, -3 and -7 randomized trials showed benefit of CDK4/6 inhibitor, ribociclib, in women with advanced-stage breast cancer. However, ribociclib-induced acute kidney injury (AKI) was not addressed in these studies. In this report, we explore AKI in breast cancer pat...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Maissoune Hajir, Ramiz Abu-Hijlih, Areej Abu Sheikha, Kholoud Alqasem, Hikmat Abdel-Razeq
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	Elsevier 2023-09-01
Reeks:	Current Problems in Cancer: Case Reports
Onderwerpen:	Breast cancer Ribociclib Acute kidney injury AKI Endocrine therapy CDK4/6 inhibitors
Online toegang:	http://www.sciencedirect.com/science/article/pii/S2666621923000273
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!